Venetoclax plus rituximab is superior to bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia - Results from pre-planned interim analysis of the randomized phase 3 Murano study Meeting Abstract
| Authors: | Seymour, J. F.; Kipps, T. J.; Eichhorst, B. F.; Hillmen, P.; D'Rozario, J. M.; Assouline, S.; Owen, C. J.; Gerecitano, J.; Robak, T.; De la Serna, J.; Jaeger, U.; Cartron, G.; Montillo, M.; Humerickhouse, R.; Punnoose, E.; Li, Y.; Boyer, M.; Humphrey, K.; Mobasher, M.; Kater, A. P. |
| Abstract Title: | Venetoclax plus rituximab is superior to bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia - Results from pre-planned interim analysis of the randomized phase 3 Murano study |
| Meeting Title: | 59th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 130 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2017 Dec 9-12 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2017-12-07 |
| Language: | English |
| ACCESSION: | WOS:000432419400004 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V130.Suppl_1.LBA-2.LBA-2 |
| Notes: | Meeting Abstract: LBA-2 -- Source: Wos |
